Cicero Diagnostics (ReceptivaDx) Company

Cicero Diagnostics is a women's healthcare diagnostic company. Endometriosis is a major focus of Cicero Diagnostics, now offering for the first time a global test for all stages of endometriosis. This disease affects over 176 million women and takes 11 years on average to diagnose. Many women spend years dealing with pain, infertility and bowel or bladder symptoms without knowing that endometriosis is the cause. Cicero Diagnostics, Inc. is the exclusive licensed provider for BCL6 analysis on endometrial tissue. ReceptivaDx (receptivadx.com) is a first of its kind test for the detection of inflammation of the uterine lining most commonly associated with endometriosis, a leading cause of infertility and implantation failure.
Industry: Reproductive Health & Contraception
Headquarters: Huntington Beach, California, United States
Founded Date: 01-01-2015
Employees Number: 1-10
Investors Number: 1
Total Funding: $1,000,000
Estimated Revenue: $1M to $10M
Last Funding Date: 2020-02-19
Last Funding Type: Grant

Visit Website
info@cicerodx.com
Register and Claim Ownership